Dresden Registry for Blood Cell Disorders
Part of Blood & lymphatic clinical trials.
This study collects medical information and blood samples from people with myelodysplastic syndrome (a blood disorder affecting how bone marrow makes blood cells) or related conditions. The goal is to understand these diseases better and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelodysplastic syndrome, a related blood disorder, or clonal changes in your blood cells (CHIP or CCUS)
- You are 18 years old or older
- You are able to understand what participating in this registry means and can sign a consent form
- You can provide a blood or bone marrow sample for the study collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This study collects information from people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that developed after cancer treatment. It does not test a new drug but helps doctors learn more about these conditions.
This study is a registry that collects information from people newly diagnosed with myelodysplastic syndrome (MDS). It helps researchers understand the condition better and may guide future studies.
This study is a database that collects information from people diagnosed with myelodysplastic syndromes. It may help researchers better understand the condition and how patients do over time.
This study is a registry that collects information from people with MDS in Asia. It helps doctors learn more about the condition and how it is managed.
This trial collects and stores biological samples (like blood or other lab materials) from people with myelodysplastic syndrome, to help researchers learn more about the disease. It may help future diagnosis or treatments, even if it doesn’t directly test a new medicine.
Hear when a new MDS (Myelodysplastic Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.